<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1456" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1456/" /><meta name="ncbi_pagename" content="Ataxia with Oculomotor Apraxia Type 1 - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Ataxia with Oculomotor Apraxia Type 1 - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Ataxia with Oculomotor Apraxia Type 1" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2015/03/19" /><meta name="citation_author" content="Paula Coutinho" /><meta name="citation_author" content="Clara Barbot" /><meta name="citation_pmid" content="20301629" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1456/" /><meta name="citation_keywords" content="AOA1" /><meta name="citation_keywords" content="AOA1" /><meta name="citation_keywords" content="Aprataxin" /><meta name="citation_keywords" content="APTX" /><meta name="citation_keywords" content="Ataxia with Oculomotor Apraxia Type 1" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Ataxia with Oculomotor Apraxia Type 1" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Paula Coutinho" /><meta name="DC.Contributor" content="Clara Barbot" /><meta name="DC.Date" content="2015/03/19" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1456/" /><meta name="description" content="Ataxia with oculomotor apraxia type 1 (AOA1) is characterized by childhood onset of slowly progressive cerebellar ataxia, followed by oculomotor apraxia and a severe primary motor peripheral axonal motor neuropathy. The first manifestation is progressive gait imbalance (mean age of onset: 4.3 years; range: 2-10 years), followed by dysarthria, then upper-limb dysmetria with mild intention tremor. Oculomotor apraxia, usually noticed a few years after the onset of ataxia, progresses to external ophthalmoplegia. All affected individuals have generalized areflexia followed by a peripheral neuropathy and quadriplegia with loss of ambulation about seven to ten years after onset. Hands and feet are short and atrophic. Chorea and upper-limb dystonia are common. Intellect remains normal in some individuals; in others, different degrees of cognitive impairment have been observed." /><meta name="og:title" content="Ataxia with Oculomotor Apraxia Type 1" /><meta name="og:type" content="book" /><meta name="og:description" content="Ataxia with oculomotor apraxia type 1 (AOA1) is characterized by childhood onset of slowly progressive cerebellar ataxia, followed by oculomotor apraxia and a severe primary motor peripheral axonal motor neuropathy. The first manifestation is progressive gait imbalance (mean age of onset: 4.3 years; range: 2-10 years), followed by dysarthria, then upper-limb dysmetria with mild intention tremor. Oculomotor apraxia, usually noticed a few years after the onset of ataxia, progresses to external ophthalmoplegia. All affected individuals have generalized areflexia followed by a peripheral neuropathy and quadriplegia with loss of ambulation about seven to ten years after onset. Hands and feet are short and atrophic. Chorea and upper-limb dystonia are common. Intellect remains normal in some individuals; in others, different degrees of cognitive impairment have been observed." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1456/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/aoa/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1456/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE885F36E0403981000000000688022B.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1456_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1456_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/as-def/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/aoa2/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1456_"><span class="title" itemprop="name">Ataxia with Oculomotor Apraxia Type 1</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonym: AOA1</div><p class="contrib-group"><span itemprop="author">Paula Coutinho</span>, MD, PhD and <span itemprop="author">Clara Barbot</span>, MD, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1456_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1456_ai__"><div class="contrib half_rhythm"><span itemprop="author">Paula Coutinho</span>, MD, PhD<div class="affiliation small">Instituto de Investiga&#x000e7;&#x000e3;o e Inova&#x000e7;&#x000e3;o em Sa&#x000fa;de<br />Centro de Gen&#x000e9;tica Preditiva e Preventiva<br />IBMC-Instituto de Biologia Molecular e Celular, UnIGENe<br />Universidade do Porto<br />Porto, Portugal<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="moc.liamg@aluapm.ohnituoc" class="oemail">moc.liamg@aluapm.ohnituoc</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Clara Barbot</span>, MD, PhD<div class="affiliation small">Instituto de Investiga&#x000e7;&#x000e3;o e Inova&#x000e7;&#x000e3;o em Sa&#x000fa;de<br />Centro de Gen&#x000e9;tica Preditiva e Preventiva<br />IBMC-Instituto de Biologia Molecular e Celular, UnIGENe<br />Universidade do Porto<br />Porto, Portugal<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="moc.liamg@tobrabaralc" class="oemail">moc.liamg@tobrabaralc</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">June 11, 2002</span>; Last Update: <span itemprop="dateModified">March 19, 2015</span>.</p><p><em>Estimated reading time: 20 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="aoa.Summary" itemprop="description"><h2 id="_aoa_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Ataxia with oculomotor apraxia type 1 (AOA1) is characterized by childhood onset of slowly progressive cerebellar ataxia, followed by oculomotor apraxia and a severe primary motor peripheral axonal motor neuropathy. The first manifestation is progressive gait imbalance (mean age of onset: 4.3 years; range: 2-10 years), followed by dysarthria, then upper-limb dysmetria with mild intention tremor. Oculomotor apraxia, usually noticed a few years after the onset of ataxia, progresses to external ophthalmoplegia. All <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have generalized areflexia followed by a peripheral neuropathy and quadriplegia with loss of ambulation about seven to ten years after onset. Hands and feet are short and atrophic. Chorea and upper-limb dystonia are common. Intellect remains normal in some individuals; in others, different degrees of cognitive impairment have been observed.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of AOA1 is based on clinical findings (including family history) and exclusion of the diagnosis of ataxia-telangiectasia. Cerebellar atrophy is visible on MRI in all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. EMG reveals axonal neuropathy in 100% of individuals with AOA1. <i>APTX</i> is the only <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> known to be associated with AOA1.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> May include physical therapy, particularly for disabilities resulting from peripheral neuropathy; a wheelchair for mobility, usually by age 15-20 years; educational support for difficulties with speaking, reading, and writing.</p><p><i>Prevention of secondary complications:</i> High-protein diet to prevent edema by restoring serum albumin concentration; low-cholesterol diet.</p><p><i>Surveillance:</i> Routine follow up with a neurologist.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>AOA1 is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being neither affected nor a carrier. Carrier testing for at-risk family members and prenatal testing for pregnancies at increased risk are possible if both pathogenic variants in a family have been identified.</p></div></div><div id="aoa.Diagnosis"><h2 id="_aoa_Diagnosis_">Diagnosis</h2><div id="aoa.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Diagnosis of ataxia with oculomotor apraxia type 1 (AOA1) should be suspected in individuals with the following combination of clinical features and test results.</p><p><b>Clinical features</b></p><ul><li class="half_rhythm"><div>Cerebellar ataxia, oculomotor apraxia, and areflexia followed by signs of severe peripheral neuropathy</div></li><li class="half_rhythm"><div>Childhood onset</div></li><li class="half_rhythm"><div>Slow progression leading to severe motor handicap</div></li><li class="half_rhythm"><div>Long survival [<a class="bk_pop" href="#aoa.REF.barbot.2001.201">Barbot et al 2001</a>]</div></li><li class="half_rhythm"><div>Absence of extraneurologic findings common in <a href="/books/n/gene/ataxia-telangiectas/">ataxia-telangiectasia</a> (telangiectasias and immunodeficiency).</div></li><li class="half_rhythm"><div>Family history consistent with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> inheritance</div></li></ul><p><b>Test results</b></p><ul><li class="half_rhythm"><div><b>MRI.</b> Cerebellar atrophy is present in all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. A very few individuals also have brain stem atrophy.</div></li><li class="half_rhythm"><div><b>EMG.</b> Signs of axonal neuropathy are found in 100% of individuals with AOA1. Note: Normal EMG results may be observed only in those investigated in the very early stages of the disease.</div></li><li class="half_rhythm"><div><b>Laboratory findings</b> that can be used to confirm the diagnosis of AOA1 in a symptomatic person include [<a class="bk_pop" href="#aoa.REF.barbot.2001.201">Barbot et al 2001</a>, <a class="bk_pop" href="#aoa.REF.le_ber.2003.2761">Le Ber et al 2003</a>]:</div><ul><li class="half_rhythm"><div><b>Serum concentration of albumin.</b> Serum concentration of albumin is decreased (&#x0003c;3.8 g/L) in 83% of individuals with disease duration of more than ten to 15 years.</div></li><li class="half_rhythm"><div><b>Serum concentration of total cholesterol.</b> Serum concentration of total cholesterol is increased (&#x0003e;5.6 mmol) in 68% of individuals with disease duration of more than ten to 15 years.</div></li><li class="half_rhythm"><div><b>Normal serum concentration of alpha-fetoprotein</b></div></li><li class="half_rhythm"><div><b>Neuropathology.</b> Nerve biopsy confirms axonal neuropathy.</div></li></ul></li></ul></div><div id="aoa.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of AOA1 is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with the detection of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>APTX</i> (see <a class="figpopup" href="/books/NBK1456/table/aoa.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figaoaTmoleculargenetictestingusedin" rid-ob="figobaoaTmoleculargenetictestingusedin">Table 1</a>).</p><p><b>One genetic testing strategy</b> is <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of <i>APTX.</i> If only one or no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found, perform <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>.</p><p><b>An alternative genetic testing strategy</b> is use of a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> that includes <i>APTX</i> and other genes of interest (see <a href="#aoa.Differential_Diagnosis">Differential Diagnosis</a>). Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</p><p>For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</p><div id="aoa.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in AOA1</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1456/table/aoa.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__aoa.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_aoa.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_aoa.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_aoa.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_aoa.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>APTX</i></td><td headers="hd_h_aoa.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>2</sup></td><td headers="hd_h_aoa.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>3</sup></td></tr><tr><td headers="hd_h_aoa.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Deletion/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> analysis&#x000a0;<sup>4</sup></td><td headers="hd_h_aoa.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>5</sup></td></tr><tr><td headers="hd_h_aoa.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>6</sup></td><td headers="hd_h_aoa.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_aoa.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="aoa.TF.1.1"><p class="no_margin">See <a href="/books/NBK1456/#aoa.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein. See <a href="#aoa.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants.</p></div></dd><dt>2. </dt><dd><div id="aoa.TF.1.2"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>3. </dt><dd><div id="aoa.TF.1.3"><p class="no_margin">All Portuguese families with AOA1 share the same <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (<a class="figpopup" href="/books/NBK1456/table/aoa.T.selected_aptx_variants/?report=objectonly" target="object" rid-figpopup="figaoaTselectedaptxvariants" rid-ob="figobaoaTselectedaptxvariants">p.Trp279Ter</a>), while Japanese families first described by <a class="bk_pop" href="#aoa.REF.uekawa.1992.1067">Uekawa et al [1992]</a> shared another pathogenic variant (<a class="figpopup" href="/books/NBK1456/table/aoa.T.selected_aptx_variants/?report=objectonly" target="object" rid-figpopup="figaoaTselectedaptxvariants" rid-ob="figobaoaTselectedaptxvariants">c.689dupT</a>).</p></div></dd><dt>4. </dt><dd><div id="aoa.TF.1.4"><p class="no_margin">Testing that identifies <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications not detectable by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of the coding and flanking <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> regions of <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> DNA. Methods used may include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and <a class="def" href="/books/n/gene/glossary/def-item/chromosomal-microarray/">chromosomal microarray</a> (CMA) that includes this gene/<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> segment.</p></div></dd><dt>5. </dt><dd><div id="aoa.TF.1.5"><p class="no_margin">Deletion of the entire <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <i>APTX</i> has been reported [<a class="bk_pop" href="#aoa.REF.amouri.2004.928">Amouri et al 2004</a>]. The frequency of alleles with partial- or whole-gene deletions is not known.</p></div></dd><dt>6. </dt><dd><div id="aoa.TF.1.6"><p class="no_margin">Scanning for pathogenic variants identified variants diagnostic for either AOA1 or AOA2 in only 20 of the 43 (46.5%) individuals with the ataxia with oculomotor apraxia <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. In other words, almost half of Portuguese families with AOA do not appear to have AOA1 or AOA2 using scanning for pathogenic variants; thus, pathogenic variants in other genes or pathogenic variants not detectable by this test method (e.g., <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions) may be causative [<a class="bk_pop" href="#aoa.REF.bras.2015.474">Bras et al 2015</a>].</p></div></dd></dl></div></div></div></div></div><div id="aoa.Clinical_Characteristics"><h2 id="_aoa_Clinical_Characteristics_">Clinical Characteristics</h2><div id="aoa.Clinical_Description"><h3>Clinical Description</h3><p>Ataxia is the main cause of disability in ataxia with oculomotor apraxia type 1 in the first stages of the disease. Later, peripheral axonal motor neuropathy dominates the clinical picture.</p><p><b>Cerebellar ataxia.</b> Symptoms are first noticed between ages two and ten years (mean: 4.3 years). In about 50% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, onset is before age seven years. Two Italian adults with cerebellar ataxia were reported having disease onset at ages 28 and 29 years [<a class="bk_pop" href="#aoa.REF.criscuolo.2004.2173">Criscuolo et al 2004</a>].</p><p>After initial normal motor development, all individuals develop cerebellar ataxia. The first manifestations of AOA1 are slowly progressive gait imbalance followed by dysarthria, then upper-limb dysmetria with mild intention tremor.</p><p><b>Oculomotor apraxia.</b> Oculomotor apraxia is present in all individuals with AOA1. It is usually noticed a few years after the onset of ataxia. Oculomotor apraxia is the most striking feature in this disorder, but can be missed on routine neurologic examination. Individuals with oculomotor apraxia do not fixate normally on objects. When asked to look to one side, they turn their heads first, with eye contraversion, after which their eyes follow to the same side in several slow saccades with head thrusts.</p><p>Blinking is exaggerated in most individuals.</p><p>Ocular movements on command are usually slightly limited; the eyes stop before reaching extreme positions of gaze. These slow eye movements appear equally on lateral and vertical gaze.</p><p>When the head is immobilized, movement of the eyes is impossible.</p><p>Oculocephalic reflexes are spared until advanced stages of the disease. When standing and turning their heads, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals lose their balance and tend to move the whole body to compensate.</p><p>Ocular pursuit movements remain normal during the first years after the appearance of oculomotor apraxia. Later, oculomotor apraxia is followed by progressive external ophthalmoplegia (beginning with upward gaze).</p><p><b>Neuropathy.</b> All individuals with AOA1 have an axonal peripheral neuropathy, with early areflexia that dominates the clinical picture in advanced phases of the disease and is the major cause of motor disability with severe weakness and wasting. Loss of independent walking happens about seven to ten years after onset; most individuals become wheelchair bound by adolescence.</p><p>Hands and feet are short and atrophic. <i>Pes cavus</i> is present in 30% of individuals and scoliosis in a few.</p><p>Vibration and postural sense are impaired only in older individuals with very long disease duration. Pain and light touch sensation are preserved.</p><p><b>Chorea.</b> About 45% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have chorea even after a long disease duration (&#x02264;51 years) [<a class="bk_pop" href="#aoa.REF.shimazaki.2002.590">Shimazaki et al 2002</a>, <a class="bk_pop" href="#aoa.REF.le_ber.2003.2761">Le Ber et al 2003</a>, <a class="bk_pop" href="#aoa.REF.sekijima.2003.1198">Sekijima et al 2003</a>, <a class="bk_pop" href="#aoa.REF.tranchant.2003.868">Tranchant et al 2003</a>, <a class="bk_pop" href="#aoa.REF.criscuolo.2004.2173">Criscuolo et al 2004</a>, <a class="bk_pop" href="#aoa.REF.habeck.2004.591">Habeck et al 2004</a>]. At onset, the percentage may be as high as 80%, but in almost 50% of affected individuals, chorea disappears over the course of the disease [<a class="bk_pop" href="#aoa.REF.le_ber.2003.2761">Le Ber et al 2003</a>].</p><p><b>Dystonia.</b> Upper-limb dystonia occurs in about 50% of individuals and may in some cases be sufficiently pronounced to justify diagnostic consideration of extrapyramidal disorders.</p><p><b>Intellect.</b> Different degrees of cognitive impairment are observed, largely independent of ethnic origin [<a class="bk_pop" href="#aoa.REF.tachi.2000.82">Tachi et al 2000</a>, <a class="bk_pop" href="#aoa.REF.moreira.2001a.501">Moreira et al 2001a</a>, <a class="bk_pop" href="#aoa.REF.shimazaki.2002.590">Shimazaki et al 2002</a>, <a class="bk_pop" href="#aoa.REF.le_ber.2003.2761">Le Ber et al 2003</a>, <a class="bk_pop" href="#aoa.REF.sekijima.2003.1198">Sekijima et al 2003</a>, <a class="bk_pop" href="#aoa.REF.criscuolo.2004.2173">Criscuolo et al 2004</a>, <a class="bk_pop" href="#aoa.REF.quinzii.2005.539">Quinzii et al 2005</a>]. Severe cognitive disability was reported in a single family [<a class="bk_pop" href="#aoa.REF.moreira.2001b.189">Moreira et al 2001b</a>].</p><p><b>Life span.</b> In the Portuguese kindreds, the age at last examination ranged from 17 to 68 years, corresponding to a disease duration of 12 to 58 years (mean: 27.5 years); two individuals died, one of an unknown cause and the other, a girl age 11 years with AOA1 who had been symptomatic for eight years, from a thalamic tumor. One Japanese individual died at age 71 years. In the cohort reported by <a class="bk_pop" href="#aoa.REF.le_ber.2003.2761">Le Ber et al [2003]</a>, disease duration was 51 years.</p><p><b>Other.</b> No signs of extraneurologic involvement are evident.</p></div><div id="aoa.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p><i>APTX</i> pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants may be associated with a later onset (age ~9 years). All other individuals with AOA1 with <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> truncating variants (<a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> or frameshift) had onset ranging between ages two and 12 years (mean: 4.6 years) [<a class="bk_pop" href="#aoa.REF.moreira.2001b.189">Moreira et al 2001b</a>, <a class="bk_pop" href="#aoa.REF.shimazaki.2002.590">Shimazaki et al 2002</a>, <a class="bk_pop" href="#aoa.REF.le_ber.2003.2761">Le Ber et al 2003</a>, <a class="bk_pop" href="#aoa.REF.sekijima.2003.1198">Sekijima et al 2003</a>, <a class="bk_pop" href="#aoa.REF.amouri.2004.928">Amouri et al 2004</a>, <a class="bk_pop" href="#aoa.REF.habeck.2004.591">Habeck et al 2004</a>, <a class="bk_pop" href="#aoa.REF.quinzii.2005.539">Quinzii et al 2005</a>].</p><p>Cognitive impairment was reported in several families of different ethnic origins who had a range of variant types, including <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, frameshift, <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a>, and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> [<a class="bk_pop" href="#aoa.REF.tachi.2000.82">Tachi et al 2000</a>, <a class="bk_pop" href="#aoa.REF.barbot.2001.201">Barbot et al 2001</a>, <a class="bk_pop" href="#aoa.REF.moreira.2001a.501">Moreira et al 2001a</a>, <a class="bk_pop" href="#aoa.REF.shimazaki.2002.590">Shimazaki et al 2002</a>, <a class="bk_pop" href="#aoa.REF.le_ber.2003.2761">Le Ber et al 2003</a>, <a class="bk_pop" href="#aoa.REF.sekijima.2003.1198">Sekijima et al 2003</a>, <a class="bk_pop" href="#aoa.REF.criscuolo.2004.2173">Criscuolo et al 2004</a>, <a class="bk_pop" href="#aoa.REF.quinzii.2005.539">Quinzii et al 2005</a>].</p><ul><li class="half_rhythm"><div>The <a class="figpopup" href="/books/NBK1456/table/aoa.T.selected_aptx_variants/?report=objectonly" target="object" rid-figpopup="figaoaTselectedaptxvariants" rid-ob="figobaoaTselectedaptxvariants">p.Trp279Ter</a> <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variant can be associated with cognitive impairment [<a class="bk_pop" href="#aoa.REF.le_ber.2003.2761">Le Ber et al 2003</a>] or normal cognitive development [<a class="bk_pop" href="#aoa.REF.moreira.2001a.501">Moreira et al 2001a</a>, <a class="bk_pop" href="#aoa.REF.le_ber.2003.2761">Le Ber et al 2003</a>, <a class="bk_pop" href="#aoa.REF.tranchant.2003.868">Tranchant et al 2003</a>].</div></li><li class="half_rhythm"><div>The presence of severe cognitive impairment in <a class="figpopup" href="/books/NBK1456/table/aoa.T.selected_aptx_variants/?report=objectonly" target="object" rid-figpopup="figaoaTselectedaptxvariants" rid-ob="figobaoaTselectedaptxvariants">p.[Glu232GlyfsTer38]+[Pro206Leu]</a> compound heterozygotes and the presence of mild cognitive impairment/borderline intelligence in the respective homozygotes is unexplained.</div></li></ul><p>Two compound heterozygotes for the <a class="figpopup" href="/books/NBK1456/table/aoa.T.selected_aptx_variants/?report=objectonly" target="object" rid-figpopup="figaoaTselectedaptxvariants" rid-ob="figobaoaTselectedaptxvariants">p.Arg199His</a> <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant and an unidentified second <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> had an atypical presentation with marked dystonia and mask-like faces in addition to the AOA1 clinical picture.</p><p>The <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> <a class="figpopup" href="/books/NBK1456/table/aoa.T.selected_aptx_variants/?report=objectonly" target="object" rid-figpopup="figaoaTselectedaptxvariants" rid-ob="figobaoaTselectedaptxvariants">p.Ala198Val</a> is associated with predominant, more severe and persistent chorea [<a class="bk_pop" href="#aoa.REF.le_ber.2003.2761">Le Ber et al 2003</a>].</p><p>In two Italian adults, <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> <a class="figpopup" href="/books/NBK1456/table/aoa.T.selected_aptx_variants/?report=objectonly" target="object" rid-figpopup="figaoaTselectedaptxvariants" rid-ob="figobaoaTselectedaptxvariants">p.Pro206Leu</a> and <a class="figpopup" href="/books/NBK1456/table/aoa.T.selected_aptx_variants/?report=objectonly" target="object" rid-figpopup="figaoaTselectedaptxvariants" rid-ob="figobaoaTselectedaptxvariants">p.His201Gln</a> pathogenic variants were associated with late-onset AOA1 (ages 28 and 29 years). In contrast, in Japanese individuals with AOA1, the <a class="figpopup" href="/books/NBK1456/table/aoa.T.selected_aptx_variants/?report=objectonly" target="object" rid-figpopup="figaoaTselectedaptxvariants" rid-ob="figobaoaTselectedaptxvariants">p.Pro206Leu</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is associated with earlier onset (age 10 years).</p><p>The pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant <a class="figpopup" href="/books/NBK1456/table/aoa.T.selected_aptx_variants/?report=objectonly" target="object" rid-figpopup="figaoaTselectedaptxvariants" rid-ob="figobaoaTselectedaptxvariants">p.Pro206Leu</a> is associated with a later onset [<a class="bk_pop" href="#aoa.REF.date.2001.184">Date et al 2001</a>] and the pathogenic variants <a class="figpopup" href="/books/NBK1456/table/aoa.T.selected_aptx_variants/?report=objectonly" target="object" rid-figpopup="figaoaTselectedaptxvariants" rid-ob="figobaoaTselectedaptxvariants">p.Val263Gly</a> and <a class="figpopup" href="/books/NBK1456/table/aoa.T.selected_aptx_variants/?report=objectonly" target="object" rid-figpopup="figaoaTselectedaptxvariants" rid-ob="figobaoaTselectedaptxvariants">p.Lys197Gln</a> with even later onset: age 15 years [<a class="bk_pop" href="#aoa.REF.tranchant.2003.868">Tranchant et al 2003</a>] and 25 years [<a class="bk_pop" href="#aoa.REF.date.2001.184">Date et al 2001</a>] respectively.</p><p>To the authors' knowledge, no correlation exists between a specific <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual's survival.</p></div><div id="aoa.Nomenclature"><h3>Nomenclature</h3><p>In Japan, AOA1 is called early-onset ataxia with oculomotor apraxia and hypoalbuminemia [<a class="bk_pop" href="#aoa.REF.date.2001.184">Date et al 2001</a>, <a class="bk_pop" href="#aoa.REF.shimazaki.2002.590">Shimazaki et al 2002</a>, <a class="bk_pop" href="#aoa.REF.sekijima.2003.1198">Sekijima et al 2003</a>].</p></div><div id="aoa.Prevalence"><h3>Prevalence</h3><p>Through a systematic population-based survey of hereditary ataxias being conducted in Portugal since 1993 [<a class="bk_pop" href="#aoa.REF.silva.1997.1377">Silva et al 1997</a>], <a href="/books/n/gene/friedreich/">Friedreich ataxia</a> (as expected) was found to be the most frequent <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> ataxia (32.8%), followed by AOA (12.6%). In Portugal there are now 42 individuals with AOA in 20 different families (AOA1= 3.6% of all autosomal recessive ataxias; AOA2= 3.3%). AOA prevalence in Portugal is estimated at 0.41 per 100,000 inhabitants. However, 20 of these individuals with AOA from 13 different families do not have either AOA1 or AOA2, illustrating AOA genetic heterogeneity [<a class="bk_pop" href="#aoa.REF.bras.2015.474">Bras et al 2015</a>].</p><p>In Japan, AOA1 appears to be the most frequent cause of <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> ataxia [<a class="bk_pop" href="#aoa.REF.uekawa.1992.1067">Uekawa et al 1992</a>, <a class="bk_pop" href="#aoa.REF.fukuhara.1995.140">Fukuhara et al 1995</a>, <a class="bk_pop" href="#aoa.REF.hanihara.1995.83">Hanihara et al 1995</a>, <a class="bk_pop" href="#aoa.REF.kubota.1995.289">Kubota et al 1995</a>, <a class="bk_pop" href="#aoa.REF.sekijima.1998.30">Sekijima et al 1998</a>, <a class="bk_pop" href="#aoa.REF.tachi.2000.82">Tachi et al 2000</a>, <a class="bk_pop" href="#aoa.REF.moreira.2001a.501">Moreira et al 2001a</a>, <a class="bk_pop" href="#aoa.REF.shimazaki.2002.590">Shimazaki et al 2002</a>, <a class="bk_pop" href="#aoa.REF.sekijima.2003.1198">Sekijima et al 2003</a>]. In the entire cohort studied by <a class="bk_pop" href="#aoa.REF.le_ber.2003.2761">Le Ber et al [2003]</a> mostly individuals of French origin with progressive cerebellar ataxia in whom Friedreich ataxia had been excluded &#x02014; the frequency of AOA1 was 5.7%; among the subset of individuals with onset before age 25 years, the frequency of AOA1 was 9.1%.</p><p>Affected individuals with pathogenic variants in <i>APTX</i> have been identified worldwide: thirteen individuals from three unrelated Tunisian families [<a class="bk_pop" href="#aoa.REF.amouri.2004.928">Amouri et al 2004</a>]; two unrelated individuals from Germany [<a class="bk_pop" href="#aoa.REF.habeck.2004.591">Habeck et al 2004</a>]; three unrelated Italian individuals [<a class="bk_pop" href="#aoa.REF.criscuolo.2004.2173">Criscuolo et al 2004</a>]; two American children [<a class="bk_pop" href="#aoa.REF.tsao.2005.619">Tsao &#x00026; Paulson 2005</a>]; and four individuals of northern European heritage with ataxia and CoQ<sub>10</sub> deficiency [<a class="bk_pop" href="#aoa.REF.quinzii.2005.539">Quinzii et al 2005</a>].</p></div></div><div id="aoa.Genetically_Related_Allelic_Disorder"><h2 id="_aoa_Genetically_Related_Allelic_Disorder_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with mutation of <i>APTX</i>.</p></div><div id="aoa.Differential_Diagnosis"><h2 id="_aoa_Differential_Diagnosis_">Differential Diagnosis</h2><p>The diagnosis of AOA1 is ruled out whenever the clinical picture includes non-progressive ataxia, microcephaly, or seizures. The differential diagnosis varies by age group.</p><p><a href="/books/n/gene/aoa2/"><b>Ataxia with oculomotor apraxia type 2</b></a>
<b>(AOA2)</b>, the disorder most likely to be confused with AOA1, is characterized by onset between age three and 30 years, cerebellar atrophy, axonal sensorimotor neuropathy, oculomotor apraxia, and elevated serum concentration of alpha-fetoprotein (AFP). See <a class="figpopup" href="/books/NBK1456/table/aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a/?report=objectonly" target="object" rid-figpopup="figaoaTcomparisonofaoa1aoa2aoa3anda" rid-ob="figobaoaTcomparisonofaoa1aoa2aoa3anda">Table 2</a>.</p><p>AOA2 is associated with pathogenic variants of <i>SETX</i>, the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> that encodes the protein senataxin [<a class="bk_pop" href="#aoa.REF.moreira.2004.225">Moreira et al 2004</a>]. In one study, AOA2 accounted for 8% of all <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> cerebellar ataxia, making it second only to Friedreich ataxia in prevalence among adults with autosomal recessive ataxia [<a class="bk_pop" href="#aoa.REF.le_ber.2004.759">Le Ber et al 2004</a>].</p><p><b>Ataxia with oculomotor apraxia type 3 (AOA3)</b> (OMIM <a href="http://omim.org/entry/615217" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">615217</a>) was described in a Saudi family in association with a pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant in <i>PIK3R5</i>. The disorder is most likely to be clinically and biochemically confused with AOA2 [<a class="bk_pop" href="#aoa.REF.al_tassan.2012.351">Al Tassan et al 2012</a>].</p><p><b>Ataxia with oculomotor apraxia type 4 (AOA4)</b> was recently described in a cohort of nine Portuguese families associated with pathogenic variants in <i>PNKP</i>. Age of onset and clinical presentation, with marked extrapyramidal manifestations and rapid progression resembles AOA1 except for cognitive impairment. AOA4 is the most frequent form of AOA in the Portuguese population [<a class="bk_pop" href="#aoa.REF.bras.2015.474">Bras et al 2015</a>].</p><div id="aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Comparison of AOA1, AOA2, AOA3 and AOA4</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1456/table/aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_lrgtbl__"><table><thead><tr><th id="hd_h_aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AOA Type</th><th id="hd_h_aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AOA1</th><th id="hd_h_aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AOA2</th><th id="hd_h_aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AOA3</th><th id="hd_h_aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AOA4</th></tr></thead><tbody><tr><td headers="hd_h_aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Mean age at onset (range)</b></td><td headers="hd_h_aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4.3 yrs (2-10)</td><td headers="hd_h_aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">13 yrs (10-14)</td><td headers="hd_h_aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">15.6 yrs (14-18)</td><td headers="hd_h_aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4.3 yrs (1-9)</td></tr><tr><td headers="hd_h_aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Evolution</b></td><td headers="hd_h_aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">More severe</td><td headers="hd_h_aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">More benign</td><td headers="hd_h_aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">More benign</td><td headers="hd_h_aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">More severe</td></tr><tr><td headers="hd_h_aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Oculomotor apraxia</b></td><td headers="hd_h_aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Early &#x00026; severe</td><td headers="hd_h_aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mild to moderate</td><td headers="hd_h_aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Late &#x00026; severe</td><td headers="hd_h_aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Early &#x00026; severe</td></tr><tr><td headers="hd_h_aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Dystonia</b></td><td headers="hd_h_aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Marked, early in the disease, disappearing w/age</td><td headers="hd_h_aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Less marked</td><td headers="hd_h_aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Not mentioned</td><td headers="hd_h_aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Marked, early in the disease</td></tr><tr><td headers="hd_h_aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Neuropathy</b></td><td headers="hd_h_aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Early &#x00026; severe</td><td headers="hd_h_aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Less severe &#x00026; beginning later in the disease</td><td headers="hd_h_aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Severe</td><td headers="hd_h_aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Early &#x00026; severe</td></tr><tr><td headers="hd_h_aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Cognitive impairment</b></td><td headers="hd_h_aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Not present</td><td headers="hd_h_aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Not present</td><td headers="hd_h_aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Not mentioned</td><td headers="hd_h_aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Often present</td></tr><tr><td headers="hd_h_aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Biochemical findings</b></td><td headers="hd_h_aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Late-onset low serum albumin &#x00026; high cholesterol; normal alpha-fetoprotein at all stages</td><td headers="hd_h_aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Early elevation of alpha-fetoprotein</td><td headers="hd_h_aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Early elevation of alpha-fetoprotein</td><td headers="hd_h_aoa.T.comparison_of_aoa1_aoa2_aoa3_and_a_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variable levels of serum albumin, cholesterol, &#x00026; alpha-fetoprotein</td></tr></tbody></table></div></div><p><b>Early childhood.</b> The diagnosis of AOA1 can be difficult to establish in very young children because all features of the disorder are not yet apparent.</p><ul><li class="half_rhythm"><div>When oculomotor apraxia is present, <a href="/books/n/gene/ataxia-telangiectas/">ataxia-telangiectasia</a> can be excluded.</div></li><li class="half_rhythm"><div><a href="/books/n/gene/joubert/">Joubert syndrome</a> is a rare, <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> disorder that affects the cerebellum and brain stem. It is characterized by the presence of a distinct respiratory pattern and profound tachypnea in the newborn period. Nonspecific features such as hypotonia, ataxia, developmental delay, and oculomotor apraxia can occur. The diagnosis of Joubert syndrome is based on the presence of these characteristic clinical features and is confirmed with cranial magnetic resonance imaging (MRI), which reveals the "molar tooth sign" resulting from hypoplasia of the cerebellar vermis and accompanying brain stem abnormalities [<a class="bk_pop" href="#aoa.REF.maria.1999.583">Maria et al 1999</a>, <a class="bk_pop" href="#aoa.REF.merritt.2003.178">Merritt 2003</a>].</div></li></ul><p><b>Adolescence</b></p><ul><li class="half_rhythm"><div><a href="/books/n/gene/friedreich/">Friedreich ataxia</a> (FRDA) can be excluded on clinical grounds. In FRDA, oculomotor apraxia is not observed and the cerebellum is normal on MRI. Molecular genetic testing of <i>FRDA</i> detects pathogenic variants in almost 100% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</div></li><li class="half_rhythm"><div><a href="/books/n/gene/aved/">Ataxia with vitamin E deficiency</a> (AVED) and <a href="/books/n/gene/coq10-def/">coenzyme Q<sub>10</sub> deficiency</a> should be considered because they are treatable disorders [<a class="bk_pop" href="#aoa.REF.musumeci.2001.849">Musumeci et al 2001</a>, <a class="bk_pop" href="#aoa.REF.quinzii.2005.539">Quinzii et al 2005</a>].</div></li><li class="half_rhythm"><div>Peripheral neuropathy with areflexia and <i>pes cavus</i> may be confused with Charcot-Marie-Tooth syndrome. See <a href="/books/n/gene/cmt/">Charcot-Marie-Tooth Hereditary Neuropathy Overview</a>.</div></li></ul><p><b>Adulthood.</b> In apparent <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases (individuals with no family history of AOA1), <a href="/books/n/gene/sca2/">SCA2</a>, which also associates cerebellar ataxia with slow eye movements, can be excluded by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>ATXN2,</i> the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> in which mutation causes SCA2 [<a class="bk_pop" href="#aoa.REF.pulst.1996.269">Pulst et al 1996</a>].</p><p>See also <a href="/books/n/gene/ataxias/">Ataxia Overview</a>.</p></div><div id="aoa.Management"><h2 id="_aoa_Management_">Management</h2><div id="aoa.Evaluations_Following_Initial_Diagno"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with ataxia with oculomotor apraxia type 1 (AOA1), the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>Examination of cognitive function</div></li><li class="half_rhythm"><div>Examination of cranial nerve function</div></li><li class="half_rhythm"><div>Extended neurologic examination of the limbs: initial inspection, tone, strength testing, reflexes, coordination, sensory testing</div></li><li class="half_rhythm"><div>Ophthalmologic examination</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="aoa.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Physical therapy may be helpful, particularly for disabilities resulting from peripheral neuropathy.</p><p>A wheelchair is usually necessary for mobility by age 15-20 years.</p><p>Educational support should be provided to compensate for difficulties in speaking (dysarthria), in reading (oculomotor apraxia), and in writing (upper-limb ataxia and weakness).</p></div><div id="aoa.Prevention_of_Secondary_Complication"><h3>Prevention of Secondary Complications</h3><p>High-protein diet to restore serum albumin concentration is indicated to prevent edema secondary to hypoalbuminemia.</p><p>Low-cholesterol diet is advised.</p></div><div id="aoa.Surveillance"><h3>Surveillance</h3><p>Routine visits to the neurologist are appropriate.</p></div><div id="aoa.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#aoa.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="aoa.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="aoa.Genetic_Counseling"><h2 id="_aoa_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="aoa.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>AOA1 is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="aoa.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Both parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> indiviudal are obligate heterozygotes (i.e., carriers of one <i>APTX</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Once an at-risk sib is known to be unaffected, the risk of his/her being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of an <i>APTX</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is 2/3.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> All the offspring of an individual with AOA1 are obligate heterozygotes (carriers) for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>APTX</i>.</p><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of an <i>APTX</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="aoa.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk family members is possible if the pathogenic variants in the family have been identified.</p></div><div id="aoa.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="aoa.Prenatal_Testing_and_Preimplantation"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>APTX</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p></div></div><div id="aoa.Resources"><h2 id="_aoa_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Associa&#x000e7;&#x000e3;o Portuguesa de Ataxias Heredit&#x000e1;rias (APAHE)</b></div><div>Rua 25 de Abril n.&#x000ba; 82</div><div>Castro Marim 8950-122</div><div>Portugal</div><div><b>Email:</b> apaheportugal@gmail.com</div><div><a href="https://www.apifarma.pt/cidadania/parcerias/associacoesdoentes/listaad/Paginas/Associa%C3%A7%C3%A3oPortuguesadeAtaxiasHeredit%C3%A1rias.aspx" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.apifarma.pt</a></div></li><li class="half_rhythm"><div><b>euro-ATAXIA (European Federation of Hereditary Ataxias)</b></div><div>Ataxia UK</div><div>Lincoln House, Kennington Park, 1-3 Brixton Road</div><div>London SW9 6DE</div><div>United Kingdom</div><div><b>Phone:</b> +44 (0) 207 582 1444</div><div><b>Email:</b> smillman@ataxia.org.uk</div><div><a href="https://www.euroataxia.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.euroataxia.org</a></div></li><li class="half_rhythm"><div><b>National Ataxia Foundation</b></div><div>2600 Fernbrook Lane</div><div>Suite 119</div><div>Minneapolis MN 55447</div><div><b>Phone:</b> 763-553-0020</div><div><b>Email:</b> naf@ataxia.org</div><div><a href="http://www.ataxia.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ataxia.org</a></div></li><li class="half_rhythm"><div><b>CoRDS Registry</b></div><div>Sanford Research</div><div>2301 East 60th Street North</div><div>Sioux Falls SD 57104</div><div><b>Phone:</b> 605-312-6423</div><div><b>Email:</b> sanfordresearch@sanfordhealth.org</div><div><a href="http://www.sanfordresearch.org/SpecialPrograms/cords/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CoRDS Registry</a></div></li></ul></div><div id="aoa.Molecular_Genetics"><h2 id="_aoa_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="aoa.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Ataxia with Oculomotor Apraxia Type 1: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1456/table/aoa.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__aoa.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_aoa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_aoa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_aoa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_aoa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_aoa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_aoa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_aoa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/54840" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>APTX</i></a></td><td headers="hd_b_aoa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=54840" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">9p21<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_aoa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q7Z2E3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Aprataxin</a></td><td headers="hd_b_aoa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/APTX" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">APTX database</a></td><td headers="hd_b_aoa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=APTX" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">APTX</a></td><td headers="hd_b_aoa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=APTX[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">APTX</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="aoa.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="aoa.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Ataxia with Oculomotor Apraxia Type 1 (<a href="/omim/208920,606350" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1456/table/aoa.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__aoa.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/208920" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">208920</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ATAXIA, EARLY-ONSET, WITH OCULOMOTOR APRAXIA AND HYPOALBUMINEMIA; EAOH</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/606350" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">606350</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">APRATAXIN; APTX</td></tr></tbody></table></div></div><div id="aoa.Molecular_Genetic_Pathogenesis"><h3>Molecular Genetic Pathogenesis</h3><p><i>APTX</i> is the only <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> known to be associated with AOA1 [<a class="bk_pop" href="#aoa.REF.date.2001.184">Date et al 2001</a>, <a class="bk_pop" href="#aoa.REF.moreira.2001b.189">Moreira et al 2001b</a>]. It encodes the protein aprataxin, which plays a role in DNA-single-strand break repair [<a class="bk_pop" href="#aoa.REF.hirano.2007.162">Hirano et al 2007</a>] and double-strand break repair machinery [<a class="bk_pop" href="#aoa.REF.clements.2004.1493">Clements et al 2004</a>].</p><p><b>Gene structure.</b>
<i>APTX</i> consists of seven exons. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1456/#aoa.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Benign variants</b> have been reported (see <a class="figpopup" href="/books/NBK1456/table/aoa.T.selected_aptx_variants/?report=objectonly" target="object" rid-figpopup="figaoaTselectedaptxvariants" rid-ob="figobaoaTselectedaptxvariants">Table 3</a>).</p><p><b>Pathogenic variants.</b> To date, 16 different pathogenic variants have been found in 37 families from different countries on three continents (<a class="figpopup" href="/books/NBK1456/table/aoa.T.selected_aptx_variants/?report=objectonly" target="object" rid-figpopup="figaoaTselectedaptxvariants" rid-ob="figobaoaTselectedaptxvariants">Table 3</a>).</p><div id="aoa.T.selected_aptx_variants" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Selected <i>APTX</i> Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1456/table/aoa.T.selected_aptx_variants/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__aoa.T.selected_aptx_variants_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_aoa.T.selected_aptx_variants_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variant Classification</th><th id="hd_h_aoa.T.selected_aptx_variants_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Exon / Intron</th><th id="hd_h_aoa.T.selected_aptx_variants_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_aoa.T.selected_aptx_variants_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change&#x000a0;<sup>2</sup></th><th id="hd_h_aoa.T.selected_aptx_variants_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Effect on Aprataxin</th><th id="hd_h_aoa.T.selected_aptx_variants_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference</th></tr></thead><tbody><tr><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Benign</b></td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Intron 1</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.134-12A&#x0003e;C</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">---</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_5" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">None</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Exon 3</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.431C&#x0003e;A</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ser144Tyr</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_6" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_1" rowspan="16" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Pathogenic</b></td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_2" rowspan="9" colspan="1" style="text-align:left;vertical-align:middle;">Exon 5</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.589A&#x0003e;C</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Lys197Gln</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_5" rowspan="6" colspan="1" style="text-align:left;vertical-align:middle;">Missense; aberrant processing</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#aoa.REF.tranchant.2003.868">Tranchant et al [2003]</a></td></tr><tr><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.593C&#x0003e;T</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala198Val</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_6" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#aoa.REF.le_ber.2003.2761">Le Ber et al [2003]</a>, <a class="bk_pop" href="#aoa.REF.criscuolo.2004.2173">Criscuolo et al [2004]</a></td></tr><tr><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.596G&#x0003e;A</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg199His</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_6" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#aoa.REF.moreira.2001b.189">Moreira et al [2001b]</a></td></tr><tr><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.602A&#x0003e;G</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.His201Arg</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_6" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#aoa.REF.shimazaki.2002.590">Shimazaki et al [2002]</a></td></tr><tr><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.603T&#x0003e;A</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.His201Gln</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_6" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#aoa.REF.criscuolo.2004.2173">Criscuolo et al [2004]</a></td></tr><tr><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.617C&#x0003e;T</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Pro206Leu</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_6" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#aoa.REF.date.2001.184">Date et al [2001]</a>, <a class="bk_pop" href="#aoa.REF.moreira.2001b.189">Moreira et al [2001b]</a>, <a class="bk_pop" href="#aoa.REF.shimazaki.2002.590">Shimazaki et al [2002]</a>, <a class="bk_pop" href="#aoa.REF.criscuolo.2004.2173">Criscuolo et al [2004]</a></td></tr><tr><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.689dupT<br />(689insT)<br />(689-690insT)</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu232GlyfsTer38</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Frameshift; truncation</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#aoa.REF.date.2001.184">Date et al [2001]</a>, <a class="bk_pop" href="#aoa.REF.moreira.2001b.189">Moreira et al [2001b]</a>, <a class="bk_pop" href="#aoa.REF.shimazaki.2002.590">Shimazaki et al [2002]</a>, <a class="bk_pop" href="#aoa.REF.sekijima.2003.1198">Sekijima et al [2003]</a></td></tr><tr><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.739 C&#x0003e;T</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg247Ter</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Stop; truncation</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#aoa.REF.mosesso.2005.485">Mosesso et al [2005]</a></td></tr><tr><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.770+1G&#x0003e;A</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Splice; truncation</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#aoa.REF.le_ber.2003.2761">Le Ber et al [2003]</a></td></tr><tr><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_2" rowspan="5" colspan="1" scope="row" style="text-align:left;vertical-align:middle;">Exon 6</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.788T&#x0003e;G</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Val263Gly</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_5" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;">Missense; aberrant processing</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#aoa.REF.date.2001.184">Date et al [2001]</a></td></tr><tr><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.800A&#x0003e;G</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asp267Gly</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_6" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#aoa.REF.le_ber.2003.2761">Le Ber et al [2003]</a></td></tr><tr><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.835T&#x0003e;C</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Trp279Arg</td></tr><tr><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.837G&#x0003e;A</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Trp279Ter</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Stop; truncation</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#aoa.REF.moreira.2001b.189">Moreira et al [2001b]</a>, <a class="bk_pop" href="#aoa.REF.le_ber.2003.2761">Le Ber et al [2003]</a>, <a class="bk_pop" href="#aoa.REF.tranchant.2003.868">Tranchant et al [2003]</a>, <a class="bk_pop" href="#aoa.REF.habeck.2004.591">Habeck et al [2004]</a>, <a class="bk_pop" href="#aoa.REF.quinzii.2005.539">Quinzii et al [2005]</a></td></tr><tr><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.841delT</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ser281LeufsTer8</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Frameshift; truncation</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#aoa.REF.date.2001.184">Date et al [2001]</a></td></tr><tr><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_2" rowspan="2" colspan="1" scope="row" style="text-align:left;vertical-align:middle;">Exon 7</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.875-1G&#x0003e;A</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Splice; truncation</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_6" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#aoa.REF.amouri.2004.928">Amouri et al [2004]</a></td></tr><tr><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Total <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a></td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td><td headers="hd_h_aoa.T.selected_aptx_variants_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No product</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="aoa.TF.3.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd><dt>2. </dt><dd><div id="aoa.TF.3.2"><p class="no_margin">Reference sequences are those of the long isoform: <a href="/protein/28329436" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_778243<wbr style="display:inline-block"></wbr>​.1</a> and <a href="/nuccore/28329435" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_175073<wbr style="display:inline-block"></wbr>​.1</a></p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>APTX</i> encodes a ubiquitously expressed protein, aprataxin. Alternative <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> on <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 3 generates two distinct <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a>. The longer transcript (<a href="/nuccore/28329435" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_175073.1</a>) is the major form found in human cell lines, with the shorter, frame-shifted form being present in lower amount [<a class="bk_pop" href="#aoa.REF.date.2001.184">Date et al 2001</a>, <a class="bk_pop" href="#aoa.REF.moreira.2001b.189">Moreira et al 2001b</a>]. The longer transcript codes for a 342-amino acid protein (<a href="/protein/28329436" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_778243.1</a>), while the shorter one encodes a 168-amino acid protein. The longer transcript is composed of three domains:</p><ul><li class="half_rhythm"><div>The PANT <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> (PNKP-AOA1 N-terminal domain), also known as putative forkhead-associated (FHA) domain [<a class="bk_pop" href="#aoa.REF.caldecott.2003.7">Caldecott 2003</a>] corresponding to the N-terminal region of aprataxin that shares 41% identity only with the N-terminus of animal polynucleotide kinase 3' phosphatase (PNKP) [<a class="bk_pop" href="#aoa.REF.jilani.1999.24176">Jilani et al 1999</a>, <a class="bk_pop" href="#aoa.REF.karimibusheri.1999.24187">Karimi-Busheri et al 1999</a>, <a class="bk_pop" href="#aoa.REF.moreira.2001b.189">Moreira et al 2001b</a>]. This domain facilitates binding to phosphorylated proteins [<a class="bk_pop" href="#aoa.REF.kijas.2006.13939">Kijas et al 2006</a>]. The PNKP (dual 5' kinase 3' phosphatase) interacts with DNA polymerase b, DNA ligase III, and XRCC1 protein, forming the single-strand break repair (SSBR) complex, following exposure to ionizing radiation and reactive oxygen species [<a class="bk_pop" href="#aoa.REF.whitehouse.2001.107">Whitehouse et al 2001</a>].</div></li><li class="half_rhythm"><div>The HIT <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> (middle domain), defined by the HIT motif, for nucleotide binding and hydrolysis. Members of the HIT super family (histidine triad) of nucleotide hydrolases/transferases [<a class="bk_pop" href="#aoa.REF.brenner.2002.9003">Brenner 2002</a>] can be divided into two main groups:</div><ul><li class="half_rhythm"><div>The Hint (histidine triad nucleotide binding)-related proteins, binding nucleotides and displaying adenosine 5'-monophosphoramidase activity [<a class="bk_pop" href="#aoa.REF.brenner.1997.231">Brenner et al 1997</a>]</div></li><li class="half_rhythm"><div>The Fhit (fragile histidine triad)-related proteins, cleaving diadenosine tetraphosphate (Ap<sub>4</sub>A), which is potentially produced during activation of the SSBR complex [<a class="bk_pop" href="#aoa.REF.mclennan.2000.73">McLennan 2000</a>]</div></li></ul></li><li class="half_rhythm"><div>The C-terminal <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>, containing a divergent zinc-finger motif [<a class="bk_pop" href="#aoa.REF.moreira.2001b.189">Moreira et al 2001b</a>], which could allow binding to DNA and/or RNA [<a class="bk_pop" href="#aoa.REF.kijas.2006.13939">Kijas et al 2006</a>]</div></li></ul><p>The presence of these three domains has suggested that aprataxin is a nuclear protein with a role in DNA repair, reminiscent of the function of the protein defective in <a href="/books/n/gene/ataxia-telangiectas/">ataxia-telangiectasia</a>, which would cause a <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> restricted to neurologic signs when mutated. Subcellular localization studies showed that aprataxin is a nuclear protein, present in both the nucleoplasm and the nucleolus [<a class="bk_pop" href="#aoa.REF.gueven.2004.1081">Gueven et al 2004</a>, <a class="bk_pop" href="#aoa.REF.sano.2004.241">Sano et al 2004</a>]. Recent experimental studies indicate that aprataxin has dual DNA binding and nucleotide hydrolase activities. Aprataxin binds to double-stranded DNA with high affinity but is also capable of binding to double-stranded RNA and to single-stranded DNA, with increased affinity for hairpin structures. Aprataxin also hydrolyses, with similar efficiency, the model histidine triad nucleotide-binding protein substrate (AMPNH<sub>2</sub>) and the fragile histidine triad protein substrate (Ap<sub>4</sub>A) [<a class="bk_pop" href="#aoa.REF.kijas.2006.13939">Kijas et al 2006</a>].</p><p>Several in vitro and in vivo studies have shown that aprataxin (long isoform) interacts with <i>XRCC1</i> [<a class="bk_pop" href="#aoa.REF.caldecott.2003.7">Caldecott 2003</a>, <a class="bk_pop" href="#aoa.REF.clements.2004.1493">Clements et al 2004</a>, <a class="bk_pop" href="#aoa.REF.gueven.2004.1081">Gueven et al 2004</a>, <a class="bk_pop" href="#aoa.REF.sano.2004.241">Sano et al 2004</a>] and <i>XRCC4</i> [<a class="bk_pop" href="#aoa.REF.clements.2004.1493">Clements et al 2004</a>], proteins implicated in single-strand and double-strand repair mechanisms, respectively. The interaction with C-terminal region of <i>XRCC1</i> is made through the 20 N-terminal amino acids of aprataxin FHA <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> [<a class="bk_pop" href="#aoa.REF.date.2004.1279">Date et al 2004</a>]. This interaction is important in maintaining the steady-state protein level of <i>XRCC1</i> [<a class="bk_pop" href="#aoa.REF.luo.2004.8356">Luo et al 2004</a>]. Interaction with another single-strand break repair protein, PARP-1, was also reported [<a class="bk_pop" href="#aoa.REF.date.2004.1279">Date et al 2004</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<a class="bk_pop" href="#aoa.REF.gueven.2004.1081">Gueven et al [2004]</a> demonstrated that pathogenic variants (even <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> ones) in <i>APTX</i> destabilize aprataxin and that cells from individuals with AOA1 are characterized by enhanced sensitivity to agents that cause single-strand breaks in DNA; however, no gross defect in single-strand break repair is apparent, even though the long isoform of aprataxin interacts with XRCC1 [<a class="bk_pop" href="#aoa.REF.caldecott.2003.7">Caldecott 2003</a>, <a class="bk_pop" href="#aoa.REF.clements.2004.1493">Clements et al 2004</a>, <a class="bk_pop" href="#aoa.REF.gueven.2004.1081">Gueven et al 2004</a>, <a class="bk_pop" href="#aoa.REF.sano.2004.241">Sano et al 2004</a>].</p><p>Even when in vitro and in vivo studies show that aprataxin interacts with XRCC4, AOA1 cell lines exhibit neither radio-resistant DNA synthesis nor a reduced ability to phosphorylate downstream targets of ATM following DNA damage, suggesting that AOA1 lacks the cell cycle checkpoint defects that are characteristic of ataxia-telangiectasia [<a class="bk_pop" href="#aoa.REF.clements.2004.1493">Clements et al 2004</a>]. Recently, cells of an individual with AOA1 <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for a stop variant showed marked, dose-related increases in induced chromosomal aberrations but did not show hypersensitivity to ionizing radiation, indicating direct involvement of aprataxin in the DNA single-strand break repair mechanisms [<a class="bk_pop" href="#aoa.REF.mosesso.2005.485">Mosesso et al 2005</a>].</p></div></div><div id="aoa.References"><h2 id="_aoa_References_">References</h2><div id="aoa.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.al_tassan.2012.351">Al Tassan N, Khalil D, Shinwari J, Al Sharif L, Bavi P, Abduljaleel Z, Abu Dhaim N, Magrashi A, Bobis S, Ahmed H, Alahmed S, Bohlega S. A missense mutation in <em>PIK3R5</em> gene in a family with ataxia and oculomotor apraxia. <span><span class="ref-journal">Hum Mutat. </span>2012;<span class="ref-vol">33</span>:351–4.</span> [<a href="/pubmed/22065524" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22065524</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.amouri.2004.928">Amouri R, Moreira MC, Zouari M, El Euch G, Barhoumi C, Kefi M, Belal S, Koenig M, Hentati F. Aprataxin gene mutations in Tunisian families. <span><span class="ref-journal">Neurology. </span>2004;<span class="ref-vol">63</span>:928–9.</span> [<a href="/pubmed/15365154" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15365154</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.barbot.2001.201">Barbot C, Coutinho P, Chorao R, Ferreira C, Barros J, Fineza I, Dias K, Monteiro J, Guimaraes A, Mendonca P, do Ceu Moreira M, Sequeiros J. Recessive ataxia with ocular apraxia: review of 22 Portuguese patients. <span><span class="ref-journal">Arch Neurol. </span>2001;<span class="ref-vol">58</span>:201–5.</span> [<a href="/pubmed/11176957" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11176957</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.bras.2015.474">Bras J, Alonso I, Barbot C, Costa MM, Darwent L, Orme T, Sequeiros J, Hardy J, Coutinho P, Guerreiro R. Mutations in PNKP cause recessive ataxia with oculomotor apraxia type 4. <span><span class="ref-journal">Am J Hum Genet. </span>2015;<span class="ref-vol">96</span>:474–9.</span> [<a href="/pmc/articles/PMC4375449/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4375449</span></a>] [<a href="/pubmed/25728773" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25728773</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.brenner.2002.9003">Brenner C. Hint, Fhit, and GalT: function, structure, evolution, and mechanism of three branches of the histidine triad superfamily of nucleotide hydrolases and transferases. <span><span class="ref-journal">Biochemistry. </span>2002;<span class="ref-vol">41</span>:9003–14.</span> [<a href="/pmc/articles/PMC2571077/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2571077</span></a>] [<a href="/pubmed/12119013" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12119013</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.brenner.1997.231">Brenner C, Garrison P, Gilmour J, Peisach D, Ringe D, Petsko GA, Lowenstein JM. Crystal structures of HINT demonstrate that histidine triad proteins are GalT-related nucleotide-binding proteins. <span><span class="ref-journal">Nat Struct Biol. </span>1997;<span class="ref-vol">4</span>:231–8.</span> [<a href="/pmc/articles/PMC2571075/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2571075</span></a>] [<a href="/pubmed/9164465" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9164465</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.caldecott.2003.7">Caldecott KW. DNA single-strand break repair and spinocerebellar ataxia. <span><span class="ref-journal">Cell. </span>2003;<span class="ref-vol">112</span>:7–10.</span> [<a href="/pubmed/12526788" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12526788</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.clements.2004.1493">Clements PM, Breslin C, Deeks ED, Byrd PJ, Ju L, Bieganowski P, Brenner C, Moreira MC, Taylor AM, Caldecott KW. The ataxia-oculomotor apraxia 1 gene product has a role distinct from ATM and interacts with the DNA strand break repair proteins XRCC1 and XRCC4. <span><span class="ref-journal">DNA Repair (Amst). </span>2004;<span class="ref-vol">3</span>:1493–502.</span> [<a href="/pubmed/15380105" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15380105</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.criscuolo.2004.2173">Criscuolo C, Mancini P, Sacca F, De Michele G, Monticelli A, Santoro L, Scarano V, Banfi S, Filla A. Ataxia with oculomotor apraxia type 1 in Southern Italy: late onset and variable phenotype. <span><span class="ref-journal">Neurology. </span>2004;<span class="ref-vol">63</span>:2173–5.</span> [<a href="/pubmed/15596775" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15596775</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.date.2004.1279">Date H, Igarashi S, Sano Y, Takahashi T, Takahashi T, Takano H, Tsuji S, Nishizawa M, Onodera O. The FHA domain of aprataxin interacts with the C-terminal region of XRCC1. <span><span class="ref-journal">Biochem Biophys Res Commun. </span>2004;<span class="ref-vol">325</span>:1279–85.</span> [<a href="/pubmed/15555565" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15555565</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.date.2001.184">Date H, Onodera O, Tanaka H, Iwabuchi K, Uekawa K, Igarashi S, Koike R, Hiroi T, Yuasa T, Awaya Y, Sakai T, Takahashi T, Nagatomo H, Sekijima Y, Kawachi I, Takiyama Y, Nishizawa M, Fukuhara N, Saito K, Sugano S, Tsuji S. Early-onset ataxia with ocular motor apraxia and hypoalbuminemia is caused by mutations in a new HIT superfamily gene. <span><span class="ref-journal">Nat Genet. </span>2001;<span class="ref-vol">29</span>:184–8.</span> [<a href="/pubmed/11586299" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11586299</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.fukuhara.1995.140">Fukuhara N, Nakajima T, Sakajiri K, Matsubara N, Fujita M. Hereditary motor and sensory neuropathy associated with cerebellar atrophy (HMSNCA): a new disease. <span><span class="ref-journal">J Neurol Sci. </span>1995;<span class="ref-vol">133</span>:140–51.</span> [<a href="/pubmed/8583217" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8583217</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.gueven.2004.1081">Gueven N, Becherel OJ, Kijas AW, Chen P, Howe O, Rudolph JH, Gatti R, Date H, Onodera O, Taucher-Scholz G, Lavin MF. Aprataxin, a novel protein that protects against genotoxic stress. <span><span class="ref-journal">Hum Mol Genet. </span>2004;<span class="ref-vol">13</span>:1081–93.</span> [<a href="/pubmed/15044383" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15044383</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.habeck.2004.591">Habeck M, Zuhlke C, Bentele KH, Unkelbach S, Kress W, Burk K, Schwinger E, Hellenbroich Y. Aprataxin mutations are a rare cause of early onset ataxia in Germany. <span><span class="ref-journal">J Neurol. </span>2004;<span class="ref-vol">251</span>:591–4.</span> [<a href="/pubmed/15164193" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15164193</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.hanihara.1995.83">Hanihara T, Kubota H, Amano N, Iwamoto H, Iwabuchi K. Siblings of early onset cerebellar ataxia with hypoalbuminemia. <span><span class="ref-journal">Rinsho Shinkeigaku. </span>1995;<span class="ref-vol">35</span>:83–6.</span> [<a href="/pubmed/7781224" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7781224</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.hirano.2007.162">Hirano M, Yamamoto A, Mori T, Lan L, Iwamoto TA, Aoki M, Shimada K, Furiya Y, Kariya S, Asai H, Yasui A, Nishiwaki T, Imoto K, Kobayashi N, Kiriyama T, Nagata T, Konishi N, Itoyama Y, Ueno S. DNA single-strand break repair is impaired in aprataxin-related ataxia. <span><span class="ref-journal">Ann Neurol. </span>2007;<span class="ref-vol">61</span>:162–74.</span> [<a href="/pubmed/17315206" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17315206</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.jilani.1999.24176">Jilani A, Ramotar D, Slack C, Ong C, Yang XM, Scherer SW, Lasko DD. Molecular cloning of the human gene, PNKP, encoding a polynucleotide kinase 3'-phosphatase and evidence for its role in repair of DNA strand breaks caused by oxidative damage. <span><span class="ref-journal">J Biol Chem. </span>1999;<span class="ref-vol">274</span>:24176–86.</span> [<a href="/pubmed/10446192" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10446192</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.karimibusheri.1999.24187">Karimi-Busheri F, Daly G, Robins P, Canas B, Pappin DJ, Sgouros J, Miller GG, Fakhrai H, Davis EM, Le Beau MM, Weinfeld M. Molecular characterization of a human DNA kinase. <span><span class="ref-journal">J Biol Chem. </span>1999;<span class="ref-vol">274</span>:24187–94.</span> [<a href="/pubmed/10446193" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10446193</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.kijas.2006.13939">Kijas AW, Harris JL, Harris JM, Lavin MF. Aprataxin Forms a Discrete Branch in the HIT (Histidine Triad) Superfamily of Proteins with Both DNA/RNA Binding and Nucleotide Hydrolase Activities. <span><span class="ref-journal">J Biol Chem. </span>2006;<span class="ref-vol">281</span>:13939–48.</span> [<a href="/pubmed/16547001" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16547001</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.kubota.1995.289">Kubota H, Sunohara N, Iwabuchi K, Hanihara A, Nagatomo H, Amano N, Kosaka K. Familial early onset cerebellar ataxia with hypoalbuminemia. <span><span class="ref-journal">No To Shinkei. </span>1995;<span class="ref-vol">47</span>:289–94.</span> [<a href="/pubmed/7669433" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7669433</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.le_ber.2004.759">Le Ber I, Bouslam N, Rivaud-Pechoux S, Guimaraes J, Benomar A, Chamayou C, Goizet C, Moreira MC, Klur S, Yahyaoui M, Agid Y, Koenig M, Stevanin G, Brice A, Durr A. Frequency and phenotypic spectrum of ataxia with oculomotor apraxia 2: a clinical and genetic study in 18 patients. <span><span class="ref-journal">Brain. </span>2004;<span class="ref-vol">127</span>:759–67.</span> [<a href="/pubmed/14736755" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14736755</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.le_ber.2003.2761">Le Ber I, Moreira MC, Rivaud-Pechoux S, Chamayou C, Ochsner F, Kuntzer T, Tardieu M, Said G, Habert MO, Demarquay G, Tannier C, Beis JM, Brice A, Koenig M, Durr A. Cerebellar ataxia with oculomotor apraxia type 1: clinical and genetic studies. <span><span class="ref-journal">Brain. </span>2003;<span class="ref-vol">126</span>:2761–72.</span> [<a href="/pubmed/14506070" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14506070</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.luo.2004.8356">Luo H, Chan DW, Yang T, Rodriguez M, Chen BP, Leng M, Mu JJ, Chen D, Songyang Z, Wang Y, Qin J. A new XRCC1-containing complex and its role in cellular survival of methyl methanesulfonate treatment. <span><span class="ref-journal">Mol Cell Biol. </span>2004;<span class="ref-vol">24</span>:8356–65.</span> [<a href="/pmc/articles/PMC516742/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC516742</span></a>] [<a href="/pubmed/15367657" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15367657</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.maria.1999.583">Maria BL, Boltshauser E, Palmer SC, Tran TX. Clinical features and revised diagnostic criteria in Joubert syndrome. <span><span class="ref-journal">J Child Neurol. </span>1999;<span class="ref-vol">14</span>:583–90.</span> [<a href="/pubmed/10488903" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10488903</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.mclennan.2000.73">McLennan AG. Dinucleoside polyphosphates-friend or foe? <span><span class="ref-journal">Pharmacol Ther. </span>2000;<span class="ref-vol">87</span>:73–89.</span> [<a href="/pubmed/11007992" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11007992</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.merritt.2003.178">Merritt L. Recognition of the clinical signs and symptoms of Joubert syndrome. <span><span class="ref-journal">Adv Neonatal Care. </span>2003;<span class="ref-vol">3</span>:178–86.</span> [<a href="/pubmed/14502525" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14502525</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.moreira.2001a.501">Moreira MC, Barbot C, Tachi N, Kozuka N, Mendonca P, Barros J, Coutinho P, Sequeiros J, Koenig M. Homozygosity mapping of Portuguese and Japanese forms of ataxia-oculomotor apraxia to 9p13, and evidence for genetic heterogeneity. <span><span class="ref-journal">Am J Hum Genet. </span>2001a;<span class="ref-vol">68</span>:501–8.</span> [<a href="/pmc/articles/PMC1235299/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1235299</span></a>] [<a href="/pubmed/11170899" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11170899</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.moreira.2001b.189">Moreira MC, Barbot C, Tachi N, Kozuka N, Uchida E, Gibson T, Mendonca P, Costa M, Barros J, Yanagisawa T, Watanabe M, Ikeda Y, Aoki M, Nagata T, Coutinho P, Sequeiros J, Koenig M. The gene mutated in ataxia-ocular apraxia 1 encodes the new HIT/Zn- finger protein aprataxin. <span><span class="ref-journal">Nat Genet. </span>2001b;<span class="ref-vol">29</span>:189–93.</span> [<a href="/pubmed/11586300" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11586300</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.moreira.2004.225">Moreira MC, Klur S, Watanabe M, Nemeth AH, Le Ber I, Moniz JC, Tranchant C, Aubourg P, Tazir M, Schols L, Pandolfo M, Schulz JB, Pouget J, Calvas P, Shizuka-Ikeda M, Shoji M, Tanaka M, Izatt L, Shaw CE, M'Zahem A, Dunne E, Bomont P, Benhassine T, Bouslam N, Stevanin G, Brice A, Guimaraes J, Mendonca P, Barbot C, Coutinho P, Sequeiros J, Durr A, Warter JM, Koenig M. Senataxin, the ortholog of a yeast RNA helicase, is mutant in ataxia-ocular apraxia 2. <span><span class="ref-journal">Nat Genet. </span>2004;<span class="ref-vol">36</span>:225–7.</span> [<a href="/pubmed/14770181" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14770181</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.mosesso.2005.485">Mosesso P, Piane M, Palitti F, Pepe G, Penna S, Chessa L. The novel human gene aprataxin is directly involved in DNA single-strand-break repair. <span><span class="ref-journal">Cell Mol Life Sci. </span>2005;<span class="ref-vol">62</span>:485–91.</span> [<a href="/pubmed/15719174" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15719174</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.musumeci.2001.849">Musumeci O, Naini A, Slonim AE, Skavin N, Hadjigeorgiou GL, Krawiecki N, Weissman BM, Tsao CY, Mendell JR, Shanske S, De Vivo DC, Hirano M, DiMauro S. Familial cerebellar ataxia with muscle coenzyme Q10 deficiency. <span><span class="ref-journal">Neurology. </span>2001;<span class="ref-vol">56</span>:849–55.</span> [<a href="/pubmed/11294920" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11294920</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.pulst.1996.269">Pulst SM, Nechiporuk A, Nechiporuk T, Gispert S, Chen XN, Lopes-Cendes I, Pearlman S, Starkman S, Orozco-Diaz G, Lunkes A, DeJong P, Rouleau GA, Auburger G, Korenberg JR, Figueroa C, Sahba S. Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. <span><span class="ref-journal">Nat Genet. </span>1996;<span class="ref-vol">14</span>:269–76.</span> [<a href="/pubmed/8896555" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8896555</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.quinzii.2005.539">Quinzii CM, Kattah AG, Naini A, Akman HO, Mootha VK, DiMauro S, Hirano M. Coenzyme Q deficiency and cerebellar ataxia associated with an aprataxin mutation. <span><span class="ref-journal">Neurology. </span>2005;<span class="ref-vol">64</span>:539–41.</span> [<a href="/pubmed/15699391" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15699391</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.sano.2004.241">Sano Y, Date H, Igarashi S, Onodera O, Oyake M, Takahashi T, Hayashi S, Morimatsu M, Takahashi H, Makifuchi T, Fukuhara N, Tsuji S. Aprataxin, the causative protein for EAOH is a nuclear protein with a potential role as a DNA repair protein. <span><span class="ref-journal">Ann Neurol. </span>2004;<span class="ref-vol">55</span>:241–9.</span> [<a href="/pubmed/14755728" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14755728</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.sekijima.2003.1198">Sekijima Y, Hashimoto T, Onodera O, Date H, Okano T, Naito K, Tsuji S, Ikeda S. Severe generalized dystonia as a presentation of a patient with aprataxin gene mutation. <span><span class="ref-journal">Mov Disord. </span>2003;<span class="ref-vol">18</span>:1198–200.</span> [<a href="/pubmed/14534929" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14534929</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.sekijima.1998.30">Sekijima Y, Ohara S, Nakagawa S, Tabata K, Yoshida K, Ishigame H, Shimizu Y, Yanagisawa N. Hereditary motor and sensory neuropathy associated with cerebellar atrophy (HMSNCA): clinical and neuropathological features of a Japanese family. <span><span class="ref-journal">J Neurol Sci. </span>1998;<span class="ref-vol">158</span>:30–7.</span> [<a href="/pubmed/9667774" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9667774</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.shimazaki.2002.590">Shimazaki H, Takiyama Y, Sakoe K, Ikeguchi K, Niijima K, Kaneko J, Namekawa M, Ogawa T, Date H, Tsuji S, Nakano I, Nishizawa M. Early-onset ataxia with ocular motor apraxia and hypoalbuminemia: the aprataxin gene mutations. <span><span class="ref-journal">Neurology. </span>2002;<span class="ref-vol">59</span>:590–5.</span> [<a href="/pubmed/12196655" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12196655</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.silva.1997.1377">Silva MC, Coutinho P, Pinheiro CD, Neves JM, Serrano P. Hereditary ataxias and spastic paraplegias: methodological aspects of a prevalence study in Portugal. <span><span class="ref-journal">J Clin Epidemiol. </span>1997;<span class="ref-vol">50</span>:1377–84.</span> [<a href="/pubmed/9449941" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9449941</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.tachi.2000.82">Tachi N, Kozuka N, Ohya K, Chiba S, Sasaki K. Hereditary cerebellar ataxia with peripheral neuropathy and mental retardation. <span><span class="ref-journal">Eur Neurol. </span>2000;<span class="ref-vol">43</span>:82–7.</span> [<a href="/pubmed/10686465" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10686465</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.tranchant.2003.868">Tranchant C, Fleury M, Moreira MC, Koenig M, Warter JM. Phenotypic variability of aprataxin gene mutations. <span><span class="ref-journal">Neurology. </span>2003;<span class="ref-vol">60</span>:868–70.</span> [<a href="/pubmed/12629250" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12629250</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.tsao.2005.619">Tsao CY, Paulson G. Type 1 ataxia with oculomotor apraxia with aprataxin gene mutations in two American children. <span><span class="ref-journal">J Child Neurol. </span>2005;<span class="ref-vol">20</span>:619–20.</span> [<a href="/pubmed/16159533" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16159533</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.uekawa.1992.1067">Uekawa K, Yuasa T, Kawasaki S, Makibuchi T, Ideta T. A hereditary ataxia associated with hypoalbuminemia and hyperlipidemia--a variant form of Friedreich's disease or a new clinical entity? <span><span class="ref-journal">Rinsho Shinkeigaku. </span>1992;<span class="ref-vol">32</span>:1067–74.</span> [<a href="/pubmed/1297549" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1297549</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="aoa.REF.whitehouse.2001.107">Whitehouse CJ, Taylor RM, Thistlethwaite A, Zhang H, Karimi-Busheri F, Lasko DD, Weinfeld M, Caldecott KW. XRCC1 stimulates human polynucleotide kinase activity at damaged DNA termini and accelerates DNA single-strand break repair. <span><span class="ref-journal">Cell. </span>2001;<span class="ref-vol">104</span>:107–17.</span> [<a href="/pubmed/11163244" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11163244</span></a>]</div></li></ul></div></div><div id="aoa.Chapter_Notes"><h2 id="_aoa_Chapter_Notes_">Chapter Notes</h2><div id="aoa.Acknowledgments"><h3>Acknowledgments</h3><p>The authors wish to express their gratitude to all patients and families for their collaboration and support, as well as to all the physicians involved in the clinical study of the families. Genetic studies were supported by funds from the Funda&#x000e7;&#x000e3;o para a Ci&#x000ea;ncia e a Tecnologia (Portuguese Ministry of Science) and the Portuguese Ministry of Health (projects STRDA/C/SAU/277/92, PECS/C/SAU/219/95, POCI/SAU-ESP/59114/04).</p></div><div id="aoa.Author_History"><h3>Author History</h3><p>Paula Coutinho, MD, PhD (2002-present)<br />Clara Barbot MD, PhD (2002-present)<br />Maria-C&#x000e9;u Moreira da Silva, MS, PhD; CNRS/INSERM/Universit&#x000e9; Louis-Pasteur (2002-2010)<br />Michel Koenig, MD, PhD; CNRS/INSERM/Universit&#x000e9; Louis-Pasteur (2002-2010)</p></div><div id="aoa.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>19 March 2015 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>22 June 2010 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>5 June 2006 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>25 May 2004 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>28 January 2004 (pc) Revision: change in test availability</div></li><li class="half_rhythm"><div>11 June 2002 (me) Review posted live</div></li><li class="half_rhythm"><div>8 November 2001 (pc) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1456</span><span class="label">PMID: <a href="/pubmed/20301629" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301629</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/as-def/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/aoa2/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1456&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1456/?report=reader">PubReader</a></li><li><a href="/books/NBK1456/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1456" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1456" style="display:none" title="Cite this Page"><div class="bk_tt">Coutinho P, Barbot C. Ataxia with Oculomotor Apraxia Type 1. 2002 Jun 11 [Updated 2015 Mar 19]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1456/pdf/Bookshelf_NBK1456.pdf">PDF version of this page</a> (460K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#aoa.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#aoa.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#aoa.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#aoa.Genetically_Related_Allelic_Disorder" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#aoa.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#aoa.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#aoa.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#aoa.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#aoa.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#aoa.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#aoa.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=54840[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">APTX</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1487312" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1487312" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1487312" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1487312" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301333" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ataxia with Oculomotor Apraxia Type 2</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ataxia with Oculomotor Apraxia Type 2<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Moreira MC, Koenig M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301284" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spinocerebellar Ataxia with Axonal Neuropathy, Autosomal Recessive</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spinocerebellar Ataxia with Axonal Neuropathy, Autosomal Recessive<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Fam HK, Salih MAM, Takashima H, Boerkoel CF. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/29356829" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Clinical, Biomarker, and Molecular Delineations and Genotype-Phenotype Correlations of Ataxia With Oculomotor Apraxia Type 1.</a><span class="source">[JAMA Neurol. 2018]</span><div class="brieflinkpop offscreen_noflow">Clinical, Biomarker, and Molecular Delineations and Genotype-Phenotype Correlations of Ataxia With Oculomotor Apraxia Type 1.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Renaud M, Moreira MC, Ben Monga B, Rodriguez D, Debs R, Charles P, Chaouch M, Ferrat F, Laurencin C, Vercueil L, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">JAMA Neurol. 2018 Apr 1; 75(4):495-502. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28277561" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Ataxia Oculomotor Apraxia Type 1 in the Siblings of a Family: A Novel Mutation.</a><span class="source">[Iran J Child Neurol. 2017]</span><div class="brieflinkpop offscreen_noflow">Ataxia Oculomotor Apraxia Type 1 in the Siblings of a Family: A Novel Mutation.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Karimzadeh P, Khayatzadeh Kakhki S, Esmail Nejad SS, Houshmand M, Ghofrani M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Iran J Child Neurol. 2017 Winter; 11(1):78-81. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/14506070" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Cerebellar ataxia with oculomotor apraxia type 1: clinical and genetic studies.</a><span class="source">[Brain. 2003]</span><div class="brieflinkpop offscreen_noflow">Cerebellar ataxia with oculomotor apraxia type 1: clinical and genetic studies.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Le Ber I, Moreira MC, Rivaud-Péchoux S, Chamayou C, Ochsner F, Kuntzer T, Tardieu M, Saïd G, Habert MO, Demarquay G, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Brain. 2003 Dec; 126(Pt 12):2761-72. Epub 2003 Sep 23.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301629" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301629" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e041327dde0891169b9c8c5">Ataxia with Oculomotor Apraxia Type 1 - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Ataxia with Oculomotor Apraxia Type 1 - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:55:51-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal101&amp;ncbi_phid=CE885F36E0403981000000000688022B&amp;ncbi_session=CE885F36E0413271_1672SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1456%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1456&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1456/&amp;ncbi_pagename=Ataxia with Oculomotor Apraxia Type 1 - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE885F36E0413271_1672SID /projects/books/PBooks@5.22 portal101 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>